LAB
STANDARD BIOTOOLS INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 24 ▼ Standard BioTools Inc. (LAB) received a Nasdaq delisting notice for…
- Jun 8 ▲ Standard BioTools (LAB) announced a transformative all-stock reverse…
- Jul 20 Standard Biotools (LAB) files S-4 for its all-stock merger with priv…
- Jul 20 ▲ Standard BioTools (LAB) filed an S-4 registration statement for its…
- Jul 22 HSR Early Termination: Standard BioTools, Inc.; Treeline…
- Jul 28 ▲ Standard BioTools announced the sale of its Mass Cytometry business…
- Sep 30 ▲ Standard BioTools terminated its prior agreement to sell its mass cy…
- Sep 30 ▲ Standard BioTools terminated its prior agreement to sell its Mass Cy…
- Oct 5 Contract: Standard BioTools Announces Agreement to Sell Microfluidic…
- Oct 9 Standard BioTools filed Amendment No. 2 to its S-4 registration stat…
- Oct 21 ▼ Standard BioTools (LAB) filed Amendment No. 3 to its S-4 registratio…
- Nov 5 ▲ 1 insider buy $46.9K at $0.6253
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $46.9K at an average $0.6253. No open-market sales.
- InstitutionsMIXED
Q3 2026: 17 added (0 new), 12 trimmed or exited.
- Short sellersSTEADY
Short interest −11.3% to 2.17M shares. 3.1 days to cover, ≈0.6% of shares.
- TrendDOWNTREND
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $2.5M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $1.5M |
| JANE STREET GROUP, LLC | TRIM | $529.4K |
| Rockefeller Capital Management L.P. | ADD | $429.0K |
| HighTower Advisors, LLC | ADD | $341.4K |
| Invesco Ltd. | ADD | $279.7K |
| Russell Investments Group, Ltd. | DOUBLED | $127.2K |
| OSAIC HOLDINGS, INC. | DOUBLED | $107.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Nov 2025Price is below the lowest target. Median implies +118%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2025 | TD Cowen MAINTAIN | Hold |
| Feb 27, 2025 | Keybanc DOWNGRADE | Sector Weight |
| Oct 31, 2024 | TD Cowen MAINTAIN | Buy |
| Aug 1, 2024 | TD Cowen MAINTAIN | Buy |
| Apr 16, 2024 | TD Cowen INITIATE | Buy |
| Apr 4, 2024 | Jefferies INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Carey Thomas D. Director Nov 5, 2026 | BUY | $46.9K |
Egholm Michael President & CEO Aug 20, 2026 | TAX W/H | $65.6K |
Mackay Sean SVP & Chief Business Officer Aug 20, 2026 | TAX W/H | $17.3K |
Kim Hanjoon Alex Chief Financial Officer Aug 20, 2026 | TAX W/H | $18.9K |
Egholm Michael President & CEO Aug 3, 2026 | TAX W/H | $314.8K |
Kim Hanjoon Alex Chief Financial Officer Jul 23, 2026 | TAX W/H | $181.2K |
Mackay Sean SVP & Chief Business Officer Jun 20, 2026 | AWARD | 500,000 sh |
Cox Troy Director Jun 18, 2026 | AWARD | 175,923 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 4 press releases · 5 bullish · 3 bearish · 1 mixed · 10 neutral- NEUTRAL 425Nov 16, 2026
Standard BioTools filed supplemental disclosures to its merger proxy statement/prospectus in response to 15 demand letters and two shareholder lawsuits alleging omitted material information in connection with its pending merger with Treeline Biosciences. The supplemental disclosures provide…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 16, 2026
Standard BioTools filed an 8-K disclosing supplemental disclosures to its merger proxy statement/prospectus for the Treeline Biosciences merger, following 15 demand letters and two shareholder lawsuits alleging omitted material information. The company voluntarily added details on financial…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 425Nov 3, 2026
Standard BioTools announced the closing of the sale of its Microfluidics business to ARCHIMED…
The closing of the Microfluidics sale removes one condition precedent for the Treeline merger. The next catalyst is the stockholder vote on the Treeline transaction, for which the proxy was mailed…
- NEUTRAL 8-KNov 3, 2026
Standard BioTools completed the previously announced sale of its Microfluidics business to…
The filing confirms the closing of a divestiture that was previously announced. With no deal value disclosed, the financial impact on Standard BioTools is unclear. Monitor upcoming quarterly filings…
All LAB filing & press-release reports (23)
- 425 reportNov 16, 2026
- 8-K reportNov 16, 2026
- 425 reportNov 3, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- EFFECT reportOct 22, 2026
- S-4/A reportOct 21, 2026
- S-4/A reportOct 9, 2026
- 425 reportOct 5, 2026
- 8-K reportOct 5, 2026
- PRESS-RELEASE reportOct 5, 2026
- 425 reportSep 30, 2026
- 8-K reportSep 30, 2026
- 425 reportJul 29, 2026
- PRESS-RELEASE reportJul 28, 2026
- S-4 reportJul 20, 2026
- 425 reportJul 20, 2026
- 425 reportJun 8, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- 8-K reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- 8-K reportFeb 24, 2026